Illumina has struggled to boost sales and consistently deliver positive earnings. Its Q4 report was largely a disappointment, and management's 2025 guidance came in below Wall Street's ...

Illumina is down 15.2% since the beginning of the year, and at $111.06 per share, it is trading 28.4% below its 52-week high of $155.15 from November 2024. Investors who bought $1,000 worth of ...

Illumina is an applied genomics technology company that was founded in 1998 with the mission statement: ‘To improve human health by unlocking the power of the genome’. Over the past two ...

(Reuters) -Shares of genetic testing company Illumina and Calvin Klein-owner PVH Corp fell on Tuesday after China placed the two companies on its "unreliable entity" list, putting them at risk of ...

SAN DIEGO, Jan. 13, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in genomic sequencing and analysis, today announced it is collaborating with NVIDIA to advance technology ...

San Diego gene sequencing giant Illumina is investing more in artificial intelligence to fuel the company’s growth strategy through a partnership with Nvidia. Nvidia — the Santa Clara tech ...

Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of the National Institutes of Health’s All of Us million-person program ...

It was put on a blacklist by the latter country. China's "blacklist of entities" now has two more entries -- Illumina and fashion conglomerate PVH-- after its government put the companies on ...

Shares of Illumina (NASDAQ: ILMN) were falling on Friday. The company's stock was down by as much as 11.4% early in the session, and was still off by 8.7% as of 2:38 p.m. ET. At that time ...

China's "blacklist of entities" now has two more entries -- Illumina and fashion conglomerate PVH-- after its government put the companies on notice late Monday. The move is clearly a retaliatory ...